Bharat Biotech India (BBIL) has said that it has gor permission to conduct human clinical trials for ‘Covaxin’, would be the first indigenous Covid-19 vaccine candidate to receive this approval.
Drug regulator Central Drugs Standard Control Organisation has given approval to BBIL.
These trials will be started throughout the country this month.
Understand, what is ‘Covaxin’ and how was it developed?
Covaxin is a vaccine candidate to developed by BBIL against the novel coronavirus (Covid-19) in collaboration with the Indian Council of Medical Research’s National Institute of Virology (NIV).
As part of this collaboration, NIV isolated a strain of the virus from an asymptomatic Covid-19 patient and transferred it to BBIL early in May.
The firm then used it to work on developing an “inactivated” vaccine–a vaccine that uses a the dead virus–at its high containment facility in Hyderabad.
“Once the vaccine is injected into a human, it has no potential to infect or replicate, since it is a killed virus. It just serves to the immune system as a dead virus and mounts an antibody response towards the virus,” said the company, adding that inactivated vaccines usually have a better safety record.
What does the approval mean for India?
This brings India a step closer to finalising a domestically developed Covid-19 vaccine for its population–a positive sign at a time when the country’s cases continue to surge, especially in the national capital.
The first phase, usually conducted on a small group of individuals, tries to find what dosage of the vaccine is safe for use, whether it is effective in building their immunity to the virus and whether there are any side effects.
The second phase is conducted on a larger group comprising hundreds of persons fitting the description of those for whom the vaccine is intended using characteristics like age and sex. This phase tests how effective the vaccine is on the population group being studied.
Vaccines, like most new drugs, are meant to follow a clinical testing process spanning four stages, starting with pre-clinical tests and ending with phase III studies conducted on thousands of patients.
YOU MAY LIKE TO READ: ICMR Teams Up With Bharat Biotech To Develop COVID-19 Vaccine
After approval from the regulator, the firm has to continue monitoring the use of its vaccine on patients and submit post-marketing surveillance details, which checks for any long-term unintended adverse effects of the product.
Bharat Biotech plans to begin its phase I and II trials in July, but is unsure of the overall timeline for testing and approving its vaccine.
“At the moment we are not sure how the vaccine is going to perform in the humans, as clinical trials are about to commence. Based on the success results of phase I and phase II, we will progress to the larger clinical trials. Thereafter, the licensure timelines will be set out upon receiving regulatory approvals,” said BBIL.
What other Indian companies are working on a Covid-19 vaccine candidate? What stage are they at?
Other Indian firms engaged in the development of Covid-19 vaccines include Zydus Cadila, Serum Institute of India and, since earlier this month, Panacea Biotec.
While Panacea is still in the pre-clinical stage, it is not clear whether Zydus and Serum have completed their preclinical studies and have also applied to CDSCO for approval to conduct human trials yet.
How does Covaxin compare to other vaccine candidates around the world? Where does it figure in the global race for a Covid-19 vaccine?
Covaxin has reached a more advanced stage of testing than two other vaccine candidates that Bharat Biotech is developing through global collaborations — the first is in collaboration with Thomas Jefferson University, while the second is with the University of Wisconsin-Madison and vaccine maker FluGen. Both these candidates are currently in the pre-clinical stage, according to the World Health Organisation’s draft landscape of Covid-19 candidate vaccines.
However, it is still far behind in the global race for a Covid-19 vaccine.
